Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
Status:
Unknown status
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of third-line and above therapy of patients with local
advanced or metastatic non-small cell lung cancer (NSCLC) with combined treatment with
launched recombinant humanized anti-PD-1 monoclonal antibody and Donafenib Tosilate